Lupin Pharmaceuticals Inc (LPI), the company's US subsidiary has launched its generic Fenofibric Acid Delayed- release capsules in the strengths of 45 mg and 135 mg, Lupin Ltd said in a statement.
The company had earlier received the final approval from the US health regulator (USFDA) for the same, it added.
The company's generic products are generic equivalent of AbbVie Inc's Trilipix delayed-release capsules in the same strengths.
As per the IMS MAT September 2013 data, Trilipix delayed- release capsules in the strengths of 45 mg and 135 mg had annual US sales of nearly $449.5 million, Lupin said.
"The capsules are indicated as co-administration therapy with statins for the treatment of mixed dyslipidemia,treatment of severe hypertriglyceridemia and primary hyperchol esterolemia or mixed dyslipidemia," it added.
Shares of Lupin Ltd were today trading at Rs 859 per scrip on BSE, up 0.42% from its previous close.